Loading...
XNAS
GALT
Market cap158mUSD
Jul 11, Last price  
2.51USD
1D
2.45%
1Q
85.93%
Jan 2017
156.12%
IPO
-79.08%
Name

Galectin Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.59%
Rev. gr., 5y
%
Revenues
0k
Net income
-47m
L+14.56%
-6,544,000-3,193,000-9,433,000-3,151,000-7,462,000-5,629,000-10,915,000-9,675,000-12,088,000-15,788,000-20,027,000-21,436,000-16,235,000-13,900,000-13,381,000-23,516,000-30,975,000-39,200,000-41,066,000-47,047,000
CFO
-42m
L+26.70%
-6,127,000-6,757,000-5,483,000-4,665,000-3,887,000-3,102,000-5,676,000-7,500,000-7,484,000-12,426,000-16,983,000-16,409,000-15,892,000-10,179,000-10,848,000-20,601,000-24,308,000-31,056,000-32,965,000-41,767,000
Earnings
Aug 11, 2025

Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
URL
https://galectintherapeutics.com/
IPO date
Sep 04, 2002
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
42,433
38,105
38,384
Unusual Expense (Income)
NOPBT
(42,433)
(38,105)
(38,384)
NOPBT Margin
Operating Taxes
424
Tax Rate
NOPAT
(42,433)
(38,105)
(38,808)
Net income
(47,047)
14.56%
(41,066)
4.76%
(39,200)
26.55%
Dividends
(91)
(97)
Dividend yield
0.11%
0.14%
Proceeds from repurchase of equity
845
40,704
10,899
BB yield
-1.05%
-40.76%
-16.24%
Debt
Debt current
21,136
46
40
Long-term debt
85,128
71,807
39,868
Deferred revenue
Other long-term liabilities
47
1,004
2,362
Net debt
91,144
46,193
21,316
Cash flow
Cash from operating activities
(41,767)
(32,965)
(31,056)
CAPEX
Cash from investing activities
Cash from financing activities
31,227
40,033
10,000
FCF
(42,380)
(37,425)
(39,534)
Balance
Cash
15,120
25,660
18,592
Long term investments
Excess cash
15,120
25,660
18,592
Stockholders' equity
(399,787)
(353,811)
(307,785)
Invested Capital
403,009
366,381
316,098
ROIC
ROCE
EV
Common stock shares outstanding
62,309
60,159
59,391
Price
1.29
-22.29%
1.66
46.90%
1.13
-45.41%
Market cap
80,379
-19.51%
99,864
48.80%
67,112
-44.60%
EV
173,246
148,280
90,151
EBITDA
(42,396)
(38,072)
(38,352)
EV/EBITDA
Interest
5,540
2,562
1,033
Interest/NOPBT